Neuroepidemiology
Original Paper
Incidence of Myasthenia gravis in the Province of FerraraCasetta I.a · Fallica E.a · Govoni V.a · Azzini C.a · Tola M.b · Granieri E.aaSezione di Clinica Neurologica, Dipartimento di Discipline Medico Chirurgiche della Comunicazione e del Comportamento, and Centro di Neuroscienze, Università degli Studi di Ferrara; bDivisione Neurologica, Dipartimento Neuroscienze, Ospedale S. Anna di Ferrara, Ferrara, Italy
Keywords: Myasthenia gravisIncidenceEpidemiology |
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Published online: September 16, 2004
Issue release date: November – December
Number of Print Pages: 4
Number of Figures: 0
Number of Tables: 0
ISSN: 0251-5350 (Print)
eISSN: 1423-0208 (Online)
For additional information: https://www.karger.com/NED
Abstract
Background: The reported annual incidence of myasthenia gravis (MG) ranges from 0.25 to 15 per million. The sex- and age-related pattern of disease incidence is still debated. Methods: An intensive descriptive study was performed in the province of Ferrara (mean population 360,950 people) over the period 1985 through 2000. Results: The average crude annual incidence rate was 2 per 100,000. We confirm a female preponderance in the total population, particularly in the youngest age groups. Conclusions: We observed an early increase in incidence in females, partly due to thymoma-associated MG, while MG without thymoma showed increasing incidence with age nonsignificantly different in the two sexes.
© 2004 S. Karger AG, Basel
Related Articles:
References
- Kurtzke JF: Epidemiology of myasthenia gravis. Adv Neurol 1978;19:545–564.
- Vincent A, Palace J, Hilton-Jones D: Myasthenia gravis. Lancet 2001;357:2122–2128.
- Aragonès JM, Bolíbar I, Bonfill X, Bufill E, Mummany A, Alonso F, Illa I: Myasthenia gravis: A higher than expected incidence in the elderly. Neurology 2003;60:1024–1026.
- Storm-Mathisen A: Epidemiology of myasthenia gravis in Norway. Acta Neurol Scand 1984;70:274–284.
- Sorensen TT, Holm EB: Myasthenia gravis in the county of Viborg, Denmark. Eur Neurol 1989;29:177–179.
- Somnier FE, Keiding N, Paulson OB: Epidemiology of myasthenia gravis in Denmark. A longitidinal and comprehensive population survey. Arch Neurol 1991;48:733–739.
- Poulas K, Tsibri E, Papanastasiou D, Tsouloufis T, Marinou M, Tsantili P, Papapetropoulos T, Tzartos SJ: Equal male and female incidence of myasthenia gravis. Neurology 2000;54:1202–1203.
- Emilia-Romagna Study Group on Clinical and Epidemiological Problems in Neurology: Incidence of myasthenia gravis in the Emilia-Romagna region: A prospective multicenter study. Neurology 1998;51:255–258.
- Jaretzki A, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB: Myasthenia gravis: Recommendations for clinical research standards. Neurology 2000;55:16–23.
- Somnier FE, Engel PJH: The occurrence of anti-titin antibodies and thymomas. A population survey of MG 1970–1999. Neurology 2002;59:92–98.
- Aarli JA: Late-onset myasthenia gravis: A changing scene. Arch Neurol 1999;56:25–27.
- Marx A, Wilisch A, Schultz A, Gattenlohner S, Nenninger R, Muller-Hermelink HK: Pathogenesis of myasthenia gravis. Virchows Arch 1997;430:355–364.
Article / Publication Details
Published online: September 16, 2004
Issue release date: November – December
Number of Print Pages: 4
Number of Figures: 0
Number of Tables: 0
ISSN: 0251-5350 (Print)
eISSN: 1423-0208 (Online)
For additional information: https://www.karger.com/NED
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
